ALKERMES reported $261.1M in Stock for its fiscal quarter ending in September of 2026.





Stock Change Date
AbbVie USD 5.31B 178M Sep/2026
Acadia Pharmaceuticals USD 40.36M 68.31M Sep/2026
ALKERMES USD 261.1M 37.86M Sep/2026
Amgen USD 6.39B 169M Sep/2026
Biogen USD 2.22B 159.9M Sep/2026
BioMarin Pharmaceutical USD 1.8B 13.54M Sep/2026
Bristol-Myers Squibb USD 2.7B 33M Sep/2026
Coherus Biosciences USD 5.67M 842K Jun/2026
Eli Lilly USD 18.19B 1.4B Sep/2026
Gilead Sciences USD 1.9B 57M Sep/2026
Heron Therapeutics USD 54.57M 2.33M Dec/2022
Ionis Pharmaceuticals USD 28.58M 22.26M Sep/2026
J&J USD 15.38B 233M Sep/2026
Merck USD 6.16B 43M Sep/2026
Nektar Therapeutics USD 14.46M 1.78M Jun/2024
Neurocrine Biosciences USD 66.1M 38.1M Sep/2026
Otsuka Holdings JPY 413.83B 82M Sep/2026
Pfizer USD 10.02B 77M Sep/2026
Regeneron Pharmaceuticals USD 2.89B 189.7M Sep/2026
Vertex Pharmaceuticals USD 2.25B 480.2M Sep/2026